Fernando Holguin
Concepts (571)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Asthma | 114 | 2024 | 2152 | 12.440 |
Why?
| Obesity | 31 | 2024 | 2530 | 3.790 |
Why?
| Air Pollutants | 18 | 2018 | 285 | 3.090 |
Why?
| Vehicle Emissions | 11 | 2017 | 60 | 2.420 |
Why?
| Anti-Asthmatic Agents | 10 | 2021 | 350 | 2.110 |
Why?
| Citrulline | 3 | 2023 | 39 | 2.090 |
Why?
| Nitric Oxide | 16 | 2020 | 834 | 2.030 |
Why?
| Lung | 25 | 2023 | 3685 | 1.670 |
Why?
| Air Pollution | 11 | 2020 | 183 | 1.600 |
Why?
| Environmental Exposure | 13 | 2020 | 382 | 1.480 |
Why?
| Minority Groups | 3 | 2021 | 232 | 1.460 |
Why?
| Arginine | 5 | 2023 | 241 | 1.450 |
Why?
| Metabolic Syndrome | 4 | 2019 | 323 | 1.370 |
Why?
| Lung Diseases | 5 | 2021 | 710 | 1.310 |
Why?
| Adrenal Cortex Hormones | 18 | 2021 | 510 | 1.200 |
Why?
| September 11 Terrorist Attacks | 2 | 2021 | 22 | 1.200 |
Why?
| Patient Selection | 2 | 2021 | 656 | 1.170 |
Why?
| Humans | 145 | 2024 | 115900 | 1.170 |
Why?
| Hospitalization | 8 | 2020 | 1761 | 1.130 |
Why?
| Dietary Supplements | 5 | 2019 | 460 | 1.120 |
Why?
| Inflammation | 14 | 2020 | 2503 | 1.070 |
Why?
| Adult | 71 | 2024 | 30817 | 1.070 |
Why?
| Respiratory Sounds | 3 | 2021 | 114 | 1.030 |
Why?
| Forced Expiratory Volume | 16 | 2021 | 522 | 1.020 |
Why?
| Oxidative Stress | 8 | 2022 | 1096 | 1.020 |
Why?
| Severity of Illness Index | 22 | 2021 | 2598 | 0.970 |
Why?
| Particulate Matter | 10 | 2020 | 217 | 0.930 |
Why?
| Bronchial Hyperreactivity | 3 | 2015 | 96 | 0.920 |
Why?
| Bronchodilator Agents | 9 | 2023 | 251 | 0.910 |
Why?
| Pulmonary Medicine | 3 | 2021 | 88 | 0.900 |
Why?
| Respiratory Function Tests | 11 | 2020 | 541 | 0.880 |
Why?
| Glucocorticoids | 4 | 2020 | 551 | 0.870 |
Why?
| Middle Aged | 54 | 2024 | 27083 | 0.860 |
Why?
| Adrenergic beta-Agonists | 3 | 2020 | 129 | 0.860 |
Why?
| Sleep Apnea, Obstructive | 2 | 2022 | 194 | 0.820 |
Why?
| Aryldialkylphosphatase | 1 | 2022 | 20 | 0.810 |
Why?
| Fatty Acids, Omega-3 | 4 | 2015 | 125 | 0.810 |
Why?
| Male | 81 | 2022 | 56126 | 0.800 |
Why?
| Microalgae | 2 | 2018 | 9 | 0.790 |
Why?
| Phenotype | 15 | 2023 | 2858 | 0.790 |
Why?
| Sleep Medicine Specialty | 1 | 2021 | 9 | 0.790 |
Why?
| Gonadal Steroid Hormones | 2 | 2020 | 124 | 0.780 |
Why?
| Female | 79 | 2022 | 60081 | 0.770 |
Why?
| Thiazolidinediones | 2 | 2015 | 143 | 0.760 |
Why?
| Pulmonary Disease, Chronic Obstructive | 6 | 2022 | 1115 | 0.730 |
Why?
| Heart Rate | 3 | 2013 | 698 | 0.730 |
Why?
| Transients and Migrants | 2 | 2018 | 22 | 0.730 |
Why?
| Fluticasone | 5 | 2021 | 87 | 0.720 |
Why?
| Young Adult | 27 | 2021 | 10517 | 0.710 |
Why?
| Social Class | 2 | 2021 | 213 | 0.700 |
Why?
| Hydroxyurea | 1 | 2019 | 30 | 0.700 |
Why?
| Respiratory Tract Diseases | 3 | 2017 | 142 | 0.700 |
Why?
| Lipoxygenase Inhibitors | 1 | 2019 | 36 | 0.700 |
Why?
| Body Mass Index | 13 | 2024 | 1982 | 0.680 |
Why?
| Leptin | 3 | 2011 | 211 | 0.680 |
Why?
| Risk Factors | 22 | 2022 | 8714 | 0.670 |
Why?
| Hypereosinophilic Syndrome | 1 | 2019 | 9 | 0.670 |
Why?
| Adiponectin | 3 | 2011 | 213 | 0.670 |
Why?
| Carotenoids | 1 | 2019 | 34 | 0.660 |
Why?
| Stramenopiles | 1 | 2018 | 1 | 0.660 |
Why?
| Biosynthetic Pathways | 1 | 2018 | 19 | 0.650 |
Why?
| Biological Products | 1 | 2021 | 172 | 0.650 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2021 | 1216 | 0.650 |
Why?
| Age of Onset | 5 | 2018 | 455 | 0.640 |
Why?
| Respiratory Mucosa | 5 | 2020 | 261 | 0.630 |
Why?
| Pulmonary Eosinophilia | 1 | 2018 | 27 | 0.630 |
Why?
| Administration, Inhalation | 14 | 2021 | 647 | 0.630 |
Why?
| Biomedical Research | 2 | 2021 | 590 | 0.620 |
Why?
| Nitrogen Dioxide | 4 | 2014 | 21 | 0.620 |
Why?
| Critical Care | 2 | 2021 | 476 | 0.610 |
Why?
| Pyridones | 1 | 2019 | 123 | 0.610 |
Why?
| Bronchoalveolar Lavage Fluid | 10 | 2020 | 609 | 0.610 |
Why?
| Immunoglobulin E | 6 | 2017 | 363 | 0.610 |
Why?
| Acclimatization | 1 | 2018 | 126 | 0.590 |
Why?
| Endoplasmic Reticulum Stress | 1 | 2018 | 92 | 0.590 |
Why?
| Fluorocarbons | 1 | 2018 | 96 | 0.570 |
Why?
| Thinness | 3 | 2021 | 87 | 0.570 |
Why?
| Nitrosative Stress | 1 | 2016 | 4 | 0.570 |
Why?
| Biomarkers | 14 | 2021 | 3473 | 0.560 |
Why?
| Respiratory Tract Infections | 4 | 2016 | 323 | 0.560 |
Why?
| Triglycerides | 1 | 2018 | 470 | 0.550 |
Why?
| Salmeterol Xinafoate | 3 | 2021 | 42 | 0.540 |
Why?
| Adolescent | 33 | 2021 | 17956 | 0.530 |
Why?
| Environmental Monitoring | 6 | 2017 | 281 | 0.530 |
Why?
| Dyslipidemias | 1 | 2017 | 155 | 0.530 |
Why?
| Fish Oils | 2 | 2005 | 25 | 0.520 |
Why?
| Soybean Oil | 2 | 2005 | 12 | 0.510 |
Why?
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2018 | 288 | 0.510 |
Why?
| United States | 24 | 2023 | 12340 | 0.510 |
Why?
| Epigenesis, Genetic | 2 | 2023 | 531 | 0.490 |
Why?
| Fatty Acids, Omega-6 | 2 | 2015 | 48 | 0.490 |
Why?
| Oxidation-Reduction | 3 | 2016 | 933 | 0.480 |
Why?
| Epithelial Cells | 7 | 2023 | 965 | 0.470 |
Why?
| Inflammation Mediators | 3 | 2014 | 481 | 0.470 |
Why?
| Reproducibility of Results | 2 | 2021 | 2814 | 0.470 |
Why?
| Exhalation | 2 | 2020 | 35 | 0.460 |
Why?
| Aged | 21 | 2020 | 19299 | 0.460 |
Why?
| Carbon Monoxide | 1 | 2013 | 68 | 0.450 |
Why?
| Child | 33 | 2023 | 18556 | 0.440 |
Why?
| Ornithine | 2 | 2023 | 21 | 0.430 |
Why?
| Hospital Mortality | 3 | 2020 | 784 | 0.430 |
Why?
| Morbidity | 3 | 2023 | 280 | 0.430 |
Why?
| Eczema | 1 | 2014 | 83 | 0.430 |
Why?
| Inhalation Exposure | 1 | 2013 | 103 | 0.430 |
Why?
| Rhinitis | 1 | 2014 | 128 | 0.410 |
Why?
| Ventricular Function, Right | 1 | 2014 | 251 | 0.410 |
Why?
| Prevalence | 7 | 2020 | 2271 | 0.400 |
Why?
| Lung Diseases, Obstructive | 1 | 2012 | 40 | 0.400 |
Why?
| Air Pollutants, Occupational | 1 | 2012 | 32 | 0.400 |
Why?
| Health Status | 1 | 2017 | 733 | 0.400 |
Why?
| Immunologic Factors | 1 | 2014 | 219 | 0.400 |
Why?
| Eosinophils | 5 | 2020 | 283 | 0.390 |
Why?
| Quality of Life | 8 | 2023 | 2392 | 0.390 |
Why?
| Cardiovascular Diseases | 3 | 2020 | 1724 | 0.390 |
Why?
| Double-Blind Method | 11 | 2019 | 1665 | 0.390 |
Why?
| Firefighters | 1 | 2012 | 38 | 0.390 |
Why?
| Dust | 1 | 2012 | 88 | 0.390 |
Why?
| Comorbidity | 10 | 2023 | 1476 | 0.380 |
Why?
| Pediatric Obesity | 1 | 2017 | 492 | 0.380 |
Why?
| Bronchoconstriction | 2 | 2010 | 27 | 0.370 |
Why?
| Intensive Care Units | 2 | 2020 | 616 | 0.370 |
Why?
| Eosinophilia | 3 | 2020 | 187 | 0.360 |
Why?
| Atherosclerosis | 1 | 2014 | 339 | 0.360 |
Why?
| Overweight | 3 | 2024 | 468 | 0.360 |
Why?
| Sputum | 6 | 2019 | 291 | 0.350 |
Why?
| Airway Resistance | 1 | 2010 | 33 | 0.350 |
Why?
| Respiratory Mechanics | 1 | 2010 | 56 | 0.350 |
Why?
| Alendronate | 2 | 2019 | 8 | 0.340 |
Why?
| Spirometry | 4 | 2023 | 256 | 0.340 |
Why?
| Hypersensitivity | 3 | 2022 | 272 | 0.340 |
Why?
| Pneumocystis carinii | 1 | 2009 | 7 | 0.330 |
Why?
| Cystic Fibrosis | 1 | 2018 | 961 | 0.330 |
Why?
| Pneumonia, Pneumocystis | 1 | 2009 | 27 | 0.330 |
Why?
| Occupational Exposure | 1 | 2012 | 263 | 0.330 |
Why?
| Heart Ventricles | 1 | 2014 | 712 | 0.330 |
Why?
| Child, Preschool | 16 | 2021 | 9176 | 0.320 |
Why?
| Precision Medicine | 3 | 2021 | 356 | 0.320 |
Why?
| Hydrogen Peroxide | 3 | 2022 | 286 | 0.320 |
Why?
| Intubation, Intratracheal | 2 | 2020 | 215 | 0.320 |
Why?
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2008 | 33 | 0.320 |
Why?
| Health Services | 1 | 2009 | 105 | 0.310 |
Why?
| Mexico | 7 | 2013 | 164 | 0.310 |
Why?
| Aged, 80 and over | 7 | 2020 | 6438 | 0.310 |
Why?
| Vasculitis | 1 | 2008 | 71 | 0.310 |
Why?
| AIDS-Related Opportunistic Infections | 1 | 2009 | 117 | 0.310 |
Why?
| Th2 Cells | 3 | 2019 | 162 | 0.300 |
Why?
| Isoprostanes | 1 | 2007 | 4 | 0.290 |
Why?
| Fatty Acids | 2 | 2021 | 385 | 0.290 |
Why?
| Bronchi | 3 | 2018 | 253 | 0.290 |
Why?
| Schools | 6 | 2021 | 401 | 0.290 |
Why?
| Multivariate Analysis | 6 | 2018 | 1444 | 0.290 |
Why?
| Breath Tests | 4 | 2018 | 85 | 0.290 |
Why?
| Refugees | 2 | 2018 | 53 | 0.290 |
Why?
| Patient Admission | 1 | 2008 | 175 | 0.280 |
Why?
| Albuterol | 5 | 2023 | 106 | 0.280 |
Why?
| Cytokines | 5 | 2019 | 1857 | 0.280 |
Why?
| Longitudinal Studies | 6 | 2020 | 2437 | 0.280 |
Why?
| Interleukin-13 | 4 | 2020 | 132 | 0.270 |
Why?
| Cross-Sectional Studies | 8 | 2024 | 4449 | 0.260 |
Why?
| Logistic Models | 4 | 2020 | 1865 | 0.260 |
Why?
| Treatment Outcome | 8 | 2020 | 9165 | 0.260 |
Why?
| Societies, Medical | 5 | 2023 | 690 | 0.260 |
Why?
| Self Report | 2 | 2019 | 701 | 0.250 |
Why?
| Sex Factors | 4 | 2018 | 1743 | 0.250 |
Why?
| Cholecalciferol | 2 | 2016 | 47 | 0.250 |
Why?
| Autonomic Nervous System | 1 | 2005 | 70 | 0.240 |
Why?
| Leukocyte Count | 4 | 2020 | 295 | 0.240 |
Why?
| Respiration, Artificial | 3 | 2020 | 525 | 0.240 |
Why?
| Microbiota | 3 | 2022 | 651 | 0.230 |
Why?
| Mexican Americans | 1 | 2004 | 101 | 0.230 |
Why?
| Prospective Studies | 8 | 2023 | 6267 | 0.220 |
Why?
| Insect Repellents | 1 | 2023 | 3 | 0.220 |
Why?
| Pilot Projects | 2 | 2019 | 1374 | 0.220 |
Why?
| Oils, Volatile | 1 | 2023 | 6 | 0.220 |
Why?
| Ixodes | 1 | 2023 | 10 | 0.220 |
Why?
| Vitamin D Deficiency | 2 | 2016 | 159 | 0.220 |
Why?
| Insect Bites and Stings | 1 | 2023 | 12 | 0.220 |
Why?
| Disease Progression | 7 | 2020 | 2424 | 0.220 |
Why?
| Vital Capacity | 4 | 2021 | 279 | 0.220 |
Why?
| Proof of Concept Study | 2 | 2019 | 44 | 0.220 |
Why?
| Incidence | 5 | 2020 | 2333 | 0.210 |
Why?
| Respiratory System | 3 | 2020 | 141 | 0.210 |
Why?
| Reflex | 1 | 2023 | 65 | 0.210 |
Why?
| Nutrition Surveys | 3 | 2018 | 225 | 0.210 |
Why?
| Vagus Nerve | 1 | 2023 | 82 | 0.210 |
Why?
| Nitric Oxide Synthase Type II | 2 | 2019 | 160 | 0.210 |
Why?
| Aedes | 1 | 2023 | 55 | 0.210 |
Why?
| Residence Characteristics | 1 | 2004 | 278 | 0.210 |
Why?
| Quercetin | 1 | 2022 | 11 | 0.210 |
Why?
| Smoking | 3 | 2020 | 1468 | 0.200 |
Why?
| Antioxidants | 4 | 2016 | 533 | 0.200 |
Why?
| Nitro Compounds | 1 | 2021 | 6 | 0.200 |
Why?
| Oleic Acids | 1 | 2021 | 10 | 0.200 |
Why?
| Waiting Lists | 1 | 2023 | 223 | 0.200 |
Why?
| Signal Transduction | 5 | 2020 | 4525 | 0.200 |
Why?
| Geography | 2 | 2021 | 185 | 0.200 |
Why?
| Hypersensitivity, Immediate | 2 | 2016 | 57 | 0.200 |
Why?
| Life Style | 2 | 2023 | 428 | 0.200 |
Why?
| Omalizumab | 1 | 2021 | 46 | 0.200 |
Why?
| Respiratory Insufficiency | 2 | 2020 | 292 | 0.190 |
Why?
| Public Health | 3 | 2018 | 439 | 0.190 |
Why?
| Lung Transplantation | 1 | 2023 | 246 | 0.190 |
Why?
| Pharmacogenomic Testing | 1 | 2021 | 54 | 0.190 |
Why?
| Self-Management | 1 | 2023 | 126 | 0.190 |
Why?
| Arginase | 1 | 2021 | 27 | 0.190 |
Why?
| Public Policy | 1 | 2021 | 61 | 0.190 |
Why?
| Socioeconomic Factors | 4 | 2018 | 1091 | 0.190 |
Why?
| Patient Advocacy | 1 | 2021 | 66 | 0.190 |
Why?
| Automobiles | 3 | 2011 | 19 | 0.190 |
Why?
| Health Services Accessibility | 2 | 2017 | 771 | 0.190 |
Why?
| Symptom Flare Up | 1 | 2020 | 40 | 0.190 |
Why?
| Case-Control Studies | 6 | 2020 | 3056 | 0.190 |
Why?
| Health Policy | 2 | 2021 | 332 | 0.180 |
Why?
| Fatty Acids, Unsaturated | 2 | 2018 | 86 | 0.180 |
Why?
| Mucus | 1 | 2021 | 55 | 0.180 |
Why?
| Diet | 2 | 2019 | 1075 | 0.180 |
Why?
| Stakeholder Participation | 1 | 2021 | 73 | 0.180 |
Why?
| Disulfides | 1 | 2021 | 91 | 0.180 |
Why?
| Geographic Mapping | 1 | 2020 | 21 | 0.180 |
Why?
| Geographic Information Systems | 1 | 2020 | 37 | 0.180 |
Why?
| Bile Acids and Salts | 1 | 2021 | 172 | 0.180 |
Why?
| Neutrophils | 3 | 2020 | 1170 | 0.180 |
Why?
| Soot | 3 | 2015 | 17 | 0.180 |
Why?
| Trust | 1 | 2021 | 108 | 0.180 |
Why?
| Tissue and Organ Procurement | 1 | 2023 | 243 | 0.180 |
Why?
| Age Factors | 5 | 2018 | 2915 | 0.180 |
Why?
| Noninvasive Ventilation | 1 | 2020 | 32 | 0.180 |
Why?
| Dyspnea | 1 | 2022 | 223 | 0.180 |
Why?
| Chemotaxis | 1 | 2020 | 132 | 0.180 |
Why?
| Uncertainty | 1 | 2020 | 98 | 0.180 |
Why?
| Puberty | 2 | 2018 | 137 | 0.170 |
Why?
| Muscarinic Antagonists | 1 | 2019 | 27 | 0.170 |
Why?
| Th1 Cells | 2 | 2017 | 125 | 0.170 |
Why?
| Gene Expression Regulation | 3 | 2019 | 2362 | 0.170 |
Why?
| Animals | 11 | 2023 | 32121 | 0.170 |
Why?
| Gene Expression | 4 | 2018 | 1442 | 0.170 |
Why?
| Nitric Oxide Synthase | 2 | 2019 | 213 | 0.170 |
Why?
| Mometasone Furoate | 1 | 2019 | 5 | 0.170 |
Why?
| Lung Neoplasms | 2 | 2023 | 2207 | 0.170 |
Why?
| Adrenergic beta-2 Receptor Agonists | 1 | 2019 | 34 | 0.170 |
Why?
| Mucin-4 | 1 | 2019 | 3 | 0.170 |
Why?
| Weight Loss | 2 | 2023 | 632 | 0.170 |
Why?
| Sialyltransferases | 1 | 2019 | 13 | 0.170 |
Why?
| DNA Methylation | 1 | 2023 | 498 | 0.170 |
Why?
| Tiotropium Bromide | 1 | 2019 | 19 | 0.170 |
Why?
| Exercise Test | 1 | 2022 | 541 | 0.170 |
Why?
| Cities | 4 | 2013 | 90 | 0.160 |
Why?
| Receptors, Adrenergic, beta-2 | 1 | 2019 | 43 | 0.160 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2020 | 141 | 0.160 |
Why?
| Immunity | 2 | 2022 | 124 | 0.160 |
Why?
| Saline Waters | 1 | 2018 | 1 | 0.160 |
Why?
| DNA, Mitochondrial | 1 | 2020 | 187 | 0.160 |
Why?
| Diagnosis, Differential | 2 | 2020 | 1358 | 0.160 |
Why?
| Gastroesophageal Reflux | 1 | 2021 | 235 | 0.160 |
Why?
| Interleukins | 1 | 2020 | 237 | 0.160 |
Why?
| Retrospective Studies | 8 | 2023 | 12616 | 0.160 |
Why?
| Immunoglobulin Fragments | 1 | 2018 | 15 | 0.160 |
Why?
| Airway Remodeling | 2 | 2016 | 60 | 0.160 |
Why?
| Moraxella | 1 | 2018 | 5 | 0.160 |
Why?
| Oxidoreductases | 1 | 2019 | 92 | 0.160 |
Why?
| Porosity | 1 | 2018 | 93 | 0.160 |
Why?
| Adsorption | 1 | 2018 | 127 | 0.160 |
Why?
| Water | 2 | 2018 | 418 | 0.160 |
Why?
| Surveys and Questionnaires | 6 | 2023 | 4671 | 0.160 |
Why?
| Lung Diseases, Interstitial | 1 | 2023 | 520 | 0.150 |
Why?
| Cold Temperature | 1 | 2018 | 125 | 0.150 |
Why?
| Corynebacterium | 1 | 2018 | 36 | 0.150 |
Why?
| Silicon Dioxide | 1 | 2018 | 94 | 0.150 |
Why?
| Air Pollution, Indoor | 2 | 2017 | 113 | 0.150 |
Why?
| Proportional Hazards Models | 2 | 2019 | 1088 | 0.150 |
Why?
| Quinolones | 1 | 2018 | 97 | 0.150 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 664 | 0.150 |
Why?
| Aminophenols | 1 | 2018 | 112 | 0.150 |
Why?
| RNA, Messenger | 3 | 2020 | 2581 | 0.140 |
Why?
| Volatile Organic Compounds | 1 | 2017 | 54 | 0.140 |
Why?
| Vocal Cord Dysfunction | 1 | 2016 | 7 | 0.140 |
Why?
| Ozone | 2 | 2015 | 105 | 0.140 |
Why?
| Health Services Needs and Demand | 1 | 2018 | 248 | 0.140 |
Why?
| Voice Quality | 1 | 2016 | 21 | 0.140 |
Why?
| Leukotriene Antagonists | 1 | 2016 | 41 | 0.140 |
Why?
| Receptor, ErbB-2 | 1 | 2019 | 302 | 0.140 |
Why?
| Bariatric Surgery | 1 | 2019 | 162 | 0.140 |
Why?
| Antigens, CD | 1 | 2019 | 442 | 0.140 |
Why?
| Vitamins | 2 | 2015 | 151 | 0.140 |
Why?
| Sleep Apnea Syndromes | 1 | 2017 | 74 | 0.140 |
Why?
| Functional Food | 1 | 2016 | 2 | 0.140 |
Why?
| Chemokines, CC | 2 | 2014 | 29 | 0.140 |
Why?
| Healthcare Disparities | 2 | 2023 | 487 | 0.140 |
Why?
| Drug Resistance | 1 | 2017 | 162 | 0.140 |
Why?
| Food Quality | 1 | 2016 | 10 | 0.140 |
Why?
| Pigments, Biological | 1 | 2016 | 12 | 0.140 |
Why?
| Income | 1 | 2017 | 170 | 0.130 |
Why?
| Forced Expiratory Flow Rates | 1 | 2015 | 12 | 0.130 |
Why?
| Zea mays | 1 | 2016 | 42 | 0.130 |
Why?
| Vermont | 1 | 2015 | 4 | 0.130 |
Why?
| Bronchoconstrictor Agents | 1 | 2015 | 14 | 0.130 |
Why?
| Crops, Agricultural | 1 | 2016 | 31 | 0.130 |
Why?
| Ibuprofen | 1 | 2016 | 73 | 0.130 |
Why?
| Methacholine Chloride | 1 | 2015 | 47 | 0.130 |
Why?
| Blood Platelets | 1 | 2019 | 350 | 0.130 |
Why?
| Anthocyanins | 1 | 2016 | 29 | 0.130 |
Why?
| Bronchial Provocation Tests | 1 | 2015 | 53 | 0.130 |
Why?
| Disease Management | 1 | 2019 | 562 | 0.130 |
Why?
| Seeds | 1 | 2016 | 74 | 0.130 |
Why?
| Secretory Leukocyte Peptidase Inhibitor | 1 | 2015 | 6 | 0.130 |
Why?
| Health Surveys | 2 | 2009 | 449 | 0.130 |
Why?
| Preventive Medicine | 1 | 2016 | 39 | 0.130 |
Why?
| Metabolome | 1 | 2018 | 284 | 0.130 |
Why?
| Lipid Metabolism | 1 | 2018 | 449 | 0.130 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2020 | 686 | 0.130 |
Why?
| Tomography, X-Ray Computed | 3 | 2021 | 2408 | 0.130 |
Why?
| Homocysteine | 1 | 2015 | 136 | 0.130 |
Why?
| Hydroxyprostaglandin Dehydrogenases | 1 | 2015 | 2 | 0.130 |
Why?
| Transportation | 1 | 2015 | 44 | 0.130 |
Why?
| Chlamydomonas reinhardtii | 1 | 2014 | 5 | 0.130 |
Why?
| Azithromycin | 1 | 2015 | 80 | 0.120 |
Why?
| Brain-Derived Neurotrophic Factor | 1 | 2015 | 106 | 0.120 |
Why?
| Fibrinogen | 1 | 2015 | 160 | 0.120 |
Why?
| Health Status Disparities | 1 | 2017 | 208 | 0.120 |
Why?
| Sleep Initiation and Maintenance Disorders | 1 | 2016 | 116 | 0.120 |
Why?
| Interleukin-27 | 1 | 2014 | 11 | 0.120 |
Why?
| Body Weight | 1 | 2019 | 872 | 0.120 |
Why?
| Pennsylvania | 4 | 2016 | 94 | 0.120 |
Why?
| Secondary Prevention | 1 | 2015 | 223 | 0.120 |
Why?
| Interleukin-6 | 2 | 2016 | 679 | 0.120 |
Why?
| Lipids | 2 | 2015 | 589 | 0.120 |
Why?
| Photosynthesis | 1 | 2014 | 66 | 0.120 |
Why?
| Pregnenediones | 1 | 2014 | 21 | 0.120 |
Why?
| Cohort Studies | 8 | 2020 | 4961 | 0.120 |
Why?
| Mice | 7 | 2023 | 15073 | 0.110 |
Why?
| Acetaminophen | 1 | 2016 | 237 | 0.110 |
Why?
| Nitrogen | 1 | 2014 | 149 | 0.110 |
Why?
| Sleep Wake Disorders | 1 | 2017 | 234 | 0.110 |
Why?
| C-Reactive Protein | 1 | 2015 | 364 | 0.110 |
Why?
| Cells, Cultured | 5 | 2020 | 3916 | 0.110 |
Why?
| Nutritional Status | 1 | 2015 | 287 | 0.110 |
Why?
| Cross-Over Studies | 3 | 2019 | 437 | 0.110 |
Why?
| Linear Models | 4 | 2018 | 778 | 0.110 |
Why?
| Prostaglandin D2 | 1 | 2013 | 21 | 0.110 |
Why?
| Receptors, Prostaglandin | 1 | 2013 | 23 | 0.110 |
Why?
| Time Factors | 2 | 2015 | 6186 | 0.110 |
Why?
| Texas | 4 | 2017 | 187 | 0.110 |
Why?
| Odds Ratio | 1 | 2015 | 970 | 0.110 |
Why?
| Chemokine CCL24 | 1 | 2012 | 9 | 0.110 |
Why?
| Metallurgy | 1 | 2012 | 8 | 0.110 |
Why?
| Dinoprost | 2 | 2009 | 31 | 0.110 |
Why?
| Weight Gain | 1 | 2015 | 454 | 0.100 |
Why?
| Macrophages, Alveolar | 3 | 2015 | 357 | 0.100 |
Why?
| Particle Size | 3 | 2011 | 341 | 0.100 |
Why?
| Mice, Inbred BALB C | 3 | 2021 | 1165 | 0.100 |
Why?
| Gene Expression Profiling | 1 | 2018 | 1547 | 0.100 |
Why?
| Receptors, Immunologic | 1 | 2013 | 201 | 0.100 |
Why?
| Interferon-gamma | 1 | 2015 | 731 | 0.100 |
Why?
| Cell Differentiation | 1 | 2019 | 1706 | 0.100 |
Why?
| Registries | 1 | 2019 | 1773 | 0.100 |
Why?
| Dose-Response Relationship, Drug | 4 | 2019 | 1868 | 0.100 |
Why?
| Mental Health | 1 | 2017 | 573 | 0.100 |
Why?
| Leukotriene E4 | 1 | 2011 | 27 | 0.090 |
Why?
| Research Design | 3 | 2021 | 947 | 0.090 |
Why?
| Glutathione Transferase | 2 | 2009 | 96 | 0.090 |
Why?
| Functional Residual Capacity | 1 | 2010 | 7 | 0.090 |
Why?
| Inhalation | 1 | 2010 | 25 | 0.090 |
Why?
| Mice, Inbred C57BL | 3 | 2021 | 4767 | 0.090 |
Why?
| Adipokines | 1 | 2009 | 43 | 0.090 |
Why?
| Alabama | 1 | 2009 | 28 | 0.090 |
Why?
| Illinois | 1 | 2009 | 37 | 0.090 |
Why?
| Nitrates | 1 | 2009 | 74 | 0.090 |
Why?
| Nitrites | 1 | 2009 | 77 | 0.090 |
Why?
| Insulin Resistance | 1 | 2017 | 1078 | 0.080 |
Why?
| Depression | 2 | 2016 | 1149 | 0.080 |
Why?
| Tyrosine | 1 | 2009 | 218 | 0.080 |
Why?
| Gases | 1 | 2009 | 42 | 0.080 |
Why?
| Plasmapheresis | 1 | 2008 | 22 | 0.080 |
Why?
| Chlorine | 1 | 2009 | 62 | 0.080 |
Why?
| Disease Models, Animal | 3 | 2021 | 3583 | 0.080 |
Why?
| Mutation | 1 | 2018 | 3369 | 0.080 |
Why?
| California | 1 | 2009 | 369 | 0.080 |
Why?
| Pneumonia | 2 | 2020 | 576 | 0.080 |
Why?
| Magnetic Resonance Imaging | 1 | 2019 | 3086 | 0.080 |
Why?
| Mice, Obese | 1 | 2007 | 52 | 0.080 |
Why?
| Glutathione | 1 | 2009 | 303 | 0.070 |
Why?
| Employer Health Costs | 1 | 2006 | 4 | 0.070 |
Why?
| Health Care Surveys | 1 | 2009 | 540 | 0.070 |
Why?
| Anti-Retroviral Agents | 1 | 2009 | 207 | 0.070 |
Why?
| Interviews as Topic | 1 | 2009 | 595 | 0.070 |
Why?
| Medication Adherence | 2 | 2023 | 536 | 0.070 |
Why?
| Anti-Bacterial Agents | 1 | 2015 | 1486 | 0.070 |
Why?
| PPAR gamma | 1 | 2007 | 185 | 0.070 |
Why?
| Clinical Protocols | 2 | 2021 | 233 | 0.070 |
Why?
| Protein Isoforms | 2 | 2019 | 339 | 0.070 |
Why?
| Phagocytosis | 1 | 2008 | 356 | 0.070 |
Why?
| Blood Transfusion | 1 | 2008 | 277 | 0.070 |
Why?
| Infant | 5 | 2018 | 8002 | 0.060 |
Why?
| Urban Health | 1 | 2005 | 75 | 0.060 |
Why?
| Coronary Disease | 1 | 2008 | 349 | 0.060 |
Why?
| Acute Lung Injury | 1 | 2009 | 302 | 0.060 |
Why?
| RNA, Ribosomal, 16S | 2 | 2018 | 492 | 0.060 |
Why?
| Homeostasis | 1 | 2009 | 576 | 0.060 |
Why?
| Health Expenditures | 1 | 2006 | 174 | 0.060 |
Why?
| Child Day Care Centers | 1 | 2005 | 33 | 0.060 |
Why?
| Renal Dialysis | 1 | 2008 | 371 | 0.060 |
Why?
| Bronchoscopy | 3 | 2012 | 245 | 0.060 |
Why?
| Biopsy | 1 | 2008 | 1056 | 0.060 |
Why?
| Survival Rate | 1 | 2009 | 1653 | 0.060 |
Why?
| Cost of Illness | 1 | 2006 | 258 | 0.060 |
Why?
| Prognosis | 2 | 2010 | 3342 | 0.060 |
Why?
| Nursing Homes | 1 | 2005 | 136 | 0.060 |
Why?
| Chemokine CCL26 | 2 | 2014 | 7 | 0.060 |
Why?
| Bronchoalveolar Lavage | 2 | 2015 | 89 | 0.060 |
Why?
| Up-Regulation | 2 | 2020 | 824 | 0.060 |
Why?
| Myocardial Ischemia | 1 | 2005 | 238 | 0.060 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2017 | 2091 | 0.060 |
Why?
| Recurrence | 2 | 2016 | 949 | 0.050 |
Why?
| Epigenomics | 1 | 2023 | 106 | 0.050 |
Why?
| National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2022 | 28 | 0.050 |
Why?
| Americas | 1 | 2022 | 21 | 0.050 |
Why?
| HIV Infections | 1 | 2016 | 2469 | 0.050 |
Why?
| Tobacco Smoke Pollution | 1 | 2005 | 221 | 0.050 |
Why?
| Latin America | 1 | 2022 | 69 | 0.050 |
Why?
| Statistics, Nonparametric | 2 | 2013 | 390 | 0.050 |
Why?
| Brazil | 1 | 2022 | 105 | 0.050 |
Why?
| Biology | 1 | 2023 | 79 | 0.050 |
Why?
| Chi-Square Distribution | 2 | 2017 | 502 | 0.050 |
Why?
| Glycocholic Acid | 1 | 2021 | 6 | 0.050 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2021 | 58 | 0.050 |
Why?
| Antigens, Dermatophagoides | 1 | 2021 | 15 | 0.050 |
Why?
| Ursodeoxycholic Acid | 1 | 2021 | 21 | 0.050 |
Why?
| Mice, Knockout | 2 | 2020 | 2607 | 0.050 |
Why?
| Respiratory Hypersensitivity | 1 | 2021 | 63 | 0.050 |
Why?
| Critical Care Outcomes | 1 | 2020 | 12 | 0.050 |
Why?
| Status Asthmaticus | 1 | 2020 | 11 | 0.050 |
Why?
| Expectorants | 1 | 2021 | 24 | 0.050 |
Why?
| Canada | 1 | 2022 | 337 | 0.050 |
Why?
| Drug Evaluation, Preclinical | 1 | 2021 | 165 | 0.050 |
Why?
| International Cooperation | 2 | 2011 | 175 | 0.050 |
Why?
| Censuses | 1 | 2020 | 18 | 0.050 |
Why?
| Altitude | 2 | 2016 | 410 | 0.050 |
Why?
| New York City | 1 | 2020 | 74 | 0.050 |
Why?
| Advisory Committees | 1 | 2021 | 208 | 0.050 |
Why?
| Exercise Tolerance | 1 | 2022 | 223 | 0.040 |
Why?
| Diet, High-Fat | 1 | 2021 | 225 | 0.040 |
Why?
| Hypoglycemic Agents | 1 | 2007 | 1008 | 0.040 |
Why?
| Primary Cell Culture | 1 | 2020 | 148 | 0.040 |
Why?
| Research | 1 | 2023 | 398 | 0.040 |
Why?
| Stroke | 1 | 2008 | 1014 | 0.040 |
Why?
| Patient Discharge | 1 | 2005 | 770 | 0.040 |
Why?
| Behavioral Risk Factor Surveillance System | 1 | 2019 | 44 | 0.040 |
Why?
| Glycoproteins | 1 | 2021 | 308 | 0.040 |
Why?
| Drug Therapy, Combination | 1 | 2021 | 961 | 0.040 |
Why?
| Drug Combinations | 1 | 2019 | 288 | 0.040 |
Why?
| Emergency Service, Hospital | 1 | 2009 | 1842 | 0.040 |
Why?
| Guidelines as Topic | 1 | 2020 | 246 | 0.040 |
Why?
| Peak Expiratory Flow Rate | 1 | 2018 | 35 | 0.040 |
Why?
| Genetic Predisposition to Disease | 1 | 2007 | 2209 | 0.040 |
Why?
| Nose | 1 | 2018 | 56 | 0.040 |
Why?
| Mouth Mucosa | 1 | 2018 | 80 | 0.040 |
Why?
| Epithelium | 1 | 2019 | 297 | 0.040 |
Why?
| Gene Knockdown Techniques | 1 | 2019 | 304 | 0.040 |
Why?
| Growth | 1 | 2018 | 56 | 0.040 |
Why?
| Early Detection of Cancer | 1 | 2021 | 340 | 0.040 |
Why?
| Chlorobenzenes | 1 | 2017 | 8 | 0.040 |
Why?
| Toluene | 1 | 2017 | 13 | 0.040 |
Why?
| Cyclohexenes | 1 | 2017 | 6 | 0.040 |
Why?
| Pentanes | 1 | 2017 | 10 | 0.040 |
Why?
| Xylenes | 1 | 2017 | 7 | 0.040 |
Why?
| Benzene | 1 | 2017 | 19 | 0.040 |
Why?
| Terpenes | 1 | 2017 | 23 | 0.040 |
Why?
| Communication | 1 | 2023 | 749 | 0.040 |
Why?
| Oils | 1 | 2017 | 19 | 0.040 |
Why?
| Adrenergic beta-Antagonists | 1 | 2019 | 293 | 0.040 |
Why?
| Genome-Wide Association Study | 1 | 2023 | 1301 | 0.040 |
Why?
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 101 | 0.040 |
Why?
| Discriminant Analysis | 1 | 2016 | 39 | 0.040 |
Why?
| Allergens | 1 | 2020 | 427 | 0.030 |
Why?
| Biomass | 1 | 2017 | 117 | 0.030 |
Why?
| Wound Healing | 1 | 2019 | 263 | 0.030 |
Why?
| Crop Production | 1 | 2016 | 2 | 0.030 |
Why?
| Succinates | 1 | 2016 | 18 | 0.030 |
Why?
| Plant Breeding | 1 | 2016 | 15 | 0.030 |
Why?
| Southwestern United States | 1 | 2016 | 92 | 0.030 |
Why?
| Sex Distribution | 1 | 2017 | 338 | 0.030 |
Why?
| Glucosides | 1 | 2016 | 36 | 0.030 |
Why?
| Maximal Midexpiratory Flow Rate | 1 | 2015 | 4 | 0.030 |
Why?
| Receptors, Interleukin-17 | 1 | 2015 | 5 | 0.030 |
Why?
| Hospital Costs | 1 | 2016 | 106 | 0.030 |
Why?
| RNA, Bacterial | 1 | 2016 | 174 | 0.030 |
Why?
| Critical Illness | 1 | 2020 | 646 | 0.030 |
Why?
| Principal Component Analysis | 1 | 2016 | 181 | 0.030 |
Why?
| Photosystem I Protein Complex | 1 | 2014 | 2 | 0.030 |
Why?
| Hydroxylation | 1 | 2015 | 28 | 0.030 |
Why?
| Proton-Motive Force | 1 | 2014 | 6 | 0.030 |
Why?
| Chlorophyll | 1 | 2014 | 12 | 0.030 |
Why?
| Thylakoids | 1 | 2014 | 3 | 0.030 |
Why?
| Patient Outcome Assessment | 1 | 2016 | 123 | 0.030 |
Why?
| Carbon Cycle | 1 | 2014 | 8 | 0.030 |
Why?
| Fever | 1 | 2016 | 280 | 0.030 |
Why?
| Disease Susceptibility | 1 | 2017 | 321 | 0.030 |
Why?
| RNA Stability | 1 | 2015 | 93 | 0.030 |
Why?
| Exons | 1 | 2015 | 303 | 0.030 |
Why?
| Starch | 1 | 2014 | 21 | 0.030 |
Why?
| Industry | 1 | 2015 | 66 | 0.030 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2023 | 1193 | 0.030 |
Why?
| Disability Evaluation | 1 | 2016 | 273 | 0.030 |
Why?
| Chemokine CXCL9 | 1 | 2014 | 22 | 0.030 |
Why?
| Interleukin-17 | 1 | 2015 | 106 | 0.030 |
Why?
| Sepsis | 1 | 2020 | 519 | 0.030 |
Why?
| Drug Resistance, Bacterial | 1 | 2015 | 156 | 0.030 |
Why?
| STAT Transcription Factors | 1 | 2014 | 14 | 0.030 |
Why?
| Geriatric Assessment | 1 | 2016 | 177 | 0.030 |
Why?
| Species Specificity | 1 | 2016 | 555 | 0.030 |
Why?
| Gene Expression Regulation, Plant | 1 | 2014 | 43 | 0.030 |
Why?
| Docosahexaenoic Acids | 1 | 2015 | 69 | 0.030 |
Why?
| Carbon Isotopes | 1 | 2014 | 112 | 0.030 |
Why?
| Plant Proteins | 1 | 2014 | 80 | 0.030 |
Why?
| Temperature | 1 | 2017 | 589 | 0.030 |
Why?
| Fluorescence | 1 | 2014 | 153 | 0.030 |
Why?
| Kaplan-Meier Estimate | 1 | 2016 | 819 | 0.030 |
Why?
| Substrate Specificity | 1 | 2015 | 356 | 0.030 |
Why?
| Exercise | 1 | 2024 | 1611 | 0.030 |
Why?
| Drug Administration Schedule | 1 | 2015 | 724 | 0.030 |
Why?
| Liver | 1 | 2021 | 1693 | 0.030 |
Why?
| Transcriptome | 1 | 2019 | 741 | 0.030 |
Why?
| Acute Disease | 1 | 2016 | 917 | 0.030 |
Why?
| Cell Line | 1 | 2019 | 2655 | 0.030 |
Why?
| Risk | 1 | 2016 | 830 | 0.030 |
Why?
| Lipocalins | 1 | 2013 | 34 | 0.030 |
Why?
| Treatment Failure | 1 | 2014 | 333 | 0.030 |
Why?
| Intramolecular Oxidoreductases | 1 | 2013 | 56 | 0.030 |
Why?
| Steel | 1 | 2012 | 7 | 0.030 |
Why?
| RNA Interference | 1 | 2015 | 438 | 0.030 |
Why?
| Meteorological Concepts | 1 | 2012 | 5 | 0.030 |
Why?
| Chemokine CCL11 | 1 | 2012 | 22 | 0.030 |
Why?
| Spatio-Temporal Analysis | 1 | 2012 | 26 | 0.030 |
Why?
| Heart Failure | 1 | 2005 | 1959 | 0.030 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 934 | 0.030 |
Why?
| Down-Regulation | 1 | 2014 | 605 | 0.030 |
Why?
| Administration, Oral | 1 | 2014 | 731 | 0.020 |
Why?
| Patient Acceptance of Health Care | 1 | 2017 | 682 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2016 | 1817 | 0.020 |
Why?
| Risk Assessment | 1 | 2020 | 3004 | 0.020 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 319 | 0.020 |
Why?
| Lipopolysaccharides | 1 | 2015 | 832 | 0.020 |
Why?
| Epidemiological Monitoring | 1 | 2011 | 47 | 0.020 |
Why?
| Pain | 1 | 2016 | 713 | 0.020 |
Why?
| Bacteria | 1 | 2016 | 731 | 0.020 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 794 | 0.020 |
Why?
| Oxygen | 1 | 2014 | 839 | 0.020 |
Why?
| Seasons | 1 | 2012 | 458 | 0.020 |
Why?
| Anxiety | 1 | 2016 | 853 | 0.020 |
Why?
| Energy Metabolism | 1 | 2014 | 712 | 0.020 |
Why?
| Chemical Hazard Release | 1 | 2009 | 1 | 0.020 |
Why?
| Railroads | 1 | 2009 | 5 | 0.020 |
Why?
| Glutathione Reductase | 1 | 2009 | 21 | 0.020 |
Why?
| Malondialdehyde | 1 | 2009 | 26 | 0.020 |
Why?
| South Carolina | 1 | 2009 | 40 | 0.020 |
Why?
| Hazardous Substances | 1 | 2009 | 11 | 0.020 |
Why?
| Glutathione Peroxidase | 1 | 2009 | 42 | 0.020 |
Why?
| Chemokines | 1 | 2010 | 214 | 0.020 |
Why?
| Voice Disorders | 1 | 2009 | 24 | 0.020 |
Why?
| Nasal Lavage Fluid | 1 | 2008 | 11 | 0.020 |
Why?
| Cough | 1 | 2009 | 109 | 0.020 |
Why?
| Cell Line, Tumor | 1 | 2015 | 2749 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2016 | 4446 | 0.020 |
Why?
| Models, Theoretical | 1 | 2011 | 527 | 0.020 |
Why?
| Immunity, Innate | 1 | 2013 | 733 | 0.020 |
Why?
| Office Visits | 1 | 2006 | 78 | 0.020 |
Why?
| Interleukin-10 | 1 | 2008 | 304 | 0.020 |
Why?
| Drug Prescriptions | 1 | 2006 | 241 | 0.020 |
Why?
| Ambulatory Care | 1 | 2006 | 480 | 0.010 |
Why?
| Algorithms | 1 | 2008 | 1493 | 0.010 |
Why?
| Apoptosis | 1 | 2008 | 2377 | 0.010 |
Why?
|
|
Holguin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|